Intellia Therapeutics, Inc. (NTLA) · Nov 5, 2026 · Earnings
Miss — EPS -$0.91 vs roughly -$0.80 consensus; revenue $7.2M vs roughly $9.7M
Intellia’s Q3 earnings missed consensus, while lonvo-z launch preparation and nex-z trial enrollment continued advancing toward key 2027 milestones.
Intellia is moving from a clinical-stage gene-editing company toward a potential first commercial launch, with lonvo-z for hereditary angioedema approaching its March 10, 2027 FDA action date while nex-z remains in Phase 3 development. That trajectory was already established before this report: the company had previously targeted MAGNITUDE-2 enrollment completion in the second half of 2026, planned a first-half 2027 lonvo-z launch, and expected cash to fund operations into 2028.
The quarter itself missed the published earnings bar. EPS was $0.91 below zero versus roughly negative $0.80 consensus, while collaboration revenue of $7.2 million was below estimates near $9.7 million to $10 million. The revenue shortfall reflects lower Regeneron collaboration revenue, not a commercial slowdown, but it still leaves the financial quarter weaker than expected.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Collaboration revenue (Financial Results) | $7.2M (-47.9%) | $13.8M | ~$9.7M |
| R&D expense (Financial Results) | $83.3M (-12.0%) | $94.7M | |
| G&A expense (Financial Results) | $46.1M (+51.2%) | $30.5M | |
| Net loss (Financial Results) | $127.5M (+25.8%) | $101.3M | |
| Diluted EPS (Statements of Operations) | $(0.91) | $(0.92) | ~$(0.80) |
| Cash and marketable securities (Balance Sheet Data) | $614.8M | $605.1M |
The operating story advanced despite the financial miss. Intellia completed MAGNITUDE-2 enrollment above its 60-patient target, and it says launch infrastructure for lonvo-z is now deployed across field operations, treatment-center engagement and payer discussions. Those are execution milestones that reduce the remaining commercialization workload, but they do not yet prove approval, launch timing or commercial uptake. 〔0〕
Funding risk looks contained through the key 2027 milestone. Cash was essentially stable year to date at $614.8 million, and management reiterated runway at least into 2028, excluding potential lonvo-z revenue and additional term-loan proceeds. The $400 million secured facility adds flexibility, but it is debt capacity rather than operating revenue and carries less strategic value than approval itself. 〔1〕
The main catalyst is now regulatory and clinical disclosure, not this quarter’s income statement. FDA acceptance, Priority Review and the March 10, 2027 PDUFA date were already disclosed in September, so this filing mostly confirms execution against that plan rather than creating a new regulatory surprise. The next identifiable information point is the November 12 lonvo-z webcast and related ACAAI presentations. 〔2〕
Bottom line: This is a mixed quarter: the reported numbers missed expectations, but the business remains on schedule for its more important 2027 approval and launch milestones. It modestly strengthens execution confidence without materially changing the central approval-dependent story.
November 12 lonvo-z investor webcast and ACAAI presentations
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!